Get started
Work

All supplemental Figures from Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

Year: 2023
Type: other
Abstract: Figure S1. Fifty percent (50%) inhibitory concentration of neratinib, afatinib and dacomitinib in Ba/F3 cells expressing different EGFR or HER2 exon 20 insertion mutations and the EGFR exon 20 insertion patient derived cell lines. to second generation EGFR-TKIs; Figure S2. Efficacy of neratinib, afatinib or dacomitinib against HER2 exon 20 insertion mutants measured in a soft agar assay; Figure S3. Patient derived EGFR exon 20 insertion cell lines; Figure S4. Comparison of amino acid sequences of exon 20 of EGFR to HER2.
DOI: 10.1158/0008-5472.22413630.v1
Authors: Takayuki Kosaka, Junko Tanizaki, Raymond M. Paranal, Hideki Endoh, Christine Lydon, Marzia Capelletti, Claire E. Repellin, Jihyun Choi, Atsuko Ogino, Antonio Calles, Dalia Ercan, Amanda J. Redig, Magda Bahcall, Geoffrey R. Oxnard, Michael J. Eck, Pasi A. Jänne
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4362421877
Cites:
Cited by:
Related to: 10